EFFICACY AND SAFETY OF A BASAL-BOLUS REGIMEN WITH INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES AFTER FAILING PREMIX INSULIN THERAPY: A MULTICENTER POSTMARKETING STUDY

SUMMARY Type 2 diabetes mellitus (T2DM) is a progressive disease, often requiring exogenous insulin therapy and treatment intensification. Despite new therapies, most patients do not reach the recommended HbA 1c target of <7%. This 6-month longitudinal study recruited Croatian patients with T2DM who did not achieve glycemic control with premixed insulin. Patients received once-daily bedtime glargine plus preprandial short-acting insulin analogues under investigators’ discretion. Endpoints included percentage of patients with HbA 1c <7% at study end and changes in mean HbA 1c and fasting plasma glucose (FPG). The intentto-treat population comprised 220 patients. At study end (6 months), 88 (40%) patients reached target HbA 1c <7%, with a mean HbA 1c decrease from 8.9±1.4% to 7.3±0.9%. The mean FPG decreased from 11.6±3.2 mmol/L to 7.4±2.3 mmol/L (P<0.0001). Glycemic regulation with premixed insulin in these